Most Recent
NSW solicitors now eligible for free couples counselling
NSW's solicitor wellbeing service, SoWell, will now offer couples counselling, with the NSW Law Society acknowledging how the mental health challenges affecting legal professional can impact personal relationships.  
Merck fails to block Pfizer’s RSV vaccine trade mark
Merck KGaA has failed to block Pfizer’s 'Abrysvo' trade mark for its RSV vaccine, with a delegate finding no likelihood of confusion with the mark for Merck’s Mavenclad MS drug despite their visual similarities. 
‘Paradigm shift’: Otsuka says High Court must reverse patent extension ruling
Otsuka Pharmaceuticals has asked the High Court to overturn a decision revoking its Abilify patent extension, saying the ruling, which limited the extension-of term scheme to active substances only, will “lead to a groundswell of court proceedings”.
Top 10 class action settlements of 2025
Class action settlements hit major milestones last year, with the year’s largest settlements totalling $1.6 billion and one case resolving for a historic $548.5 million.
Judge won’t put Bupa class action on ice pending possible appeal
A judge hearing a class action alleging Bupa failed to provide promised levels of care to residents has said she won’t put the case on ice pending the aged care provider's potential appeal of a decision declining to toss the case. 
Drug makers back in court five years after settling case over Merck TM
German drug maker Merck KGaA is fighting US drug company Merck Sharp & Dohme over the alleged use of the ‘Merck’ mark in Australia, five years after their intellectual property spat was settled. 
Lanzer patient must serve surgeon, not just his lawyers: court
A medical assessment served under the Wrongs Act by a patient of Dr Daniel Lanzer needed to come to the attention of the surgeon himself, not just his solicitors, despite the lawyers being authorised to receive other documents in the case, an appeals court has found. 
Bupa class action dodges summary dismissal application
A class action against Bupa alleging the aged care provider failed to provide promised levels of care to residents can proceed, with a judge finding the case is not "fatally flawed".
Mayne says it’s not on hook for break fee over failed Cosette merger
Mayne Pharma says it, and not US drug maker Cosette, has terminated their $672 million merger agreement and that it is therefore not on the hook for a break fee.
Bupa must pay $35M in unconscionable conduct case
A court has slapped private health insurer Bupa with a $35 million penalty after it admitted to misleading thousands of customers about their benefits for over five years.